Molecular Testing and Treatment Strategies in <i>RET</i>-Rearranged NSCLC Patients: Stay on Target to Look Forward
<i>RET</i> alterations are recognized as key oncogenic drivers in different cancer types, including non-small cell lung cancer (NSCLC). Multikinase inhibitors (MKIs) with anti-<i>RET</i> activities resulted in variable efficacy with significant toxicities because of low targe...
Main Authors: | Maria Lucia Reale, Valentina Bertaglia, Angela Listì, Silvia Novello, Francesco Passiglia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Journal of Molecular Pathology |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-5261/3/1/3 |
Similar Items
-
RET Inhibitors in Non-Small-Cell Lung Cancer
by: Priscilla Cascetta, et al.
Published: (2021-09-01) -
Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
by: Paolo D. d'Arienzo, MD, MRCP, et al.
Published: (2023-12-01) -
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
by: Sara Fancelli, et al.
Published: (2021-03-01) -
Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
by: Sai-Hong Ignatius Ou, MD, PhD, et al.
Published: (2020-06-01) -
<i>RET</i>-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
by: Antoine Desilets, et al.
Published: (2023-08-01)